Loading clinical trials...
Loading clinical trials...
A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Conditions
Interventions
SHR-A2102 for Injection
Adebrelimab Injection
+3 more
Locations
1
China
Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, China
Start Date
July 30, 2024
Primary Completion Date
October 1, 2026
Completion Date
October 1, 2026
Last Updated
December 23, 2025
NCT06996782
NCT06955988
NCT07175220
NCT06581419
NCT05450692
NCT02855125
Lead Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions